Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Smith, R. P.
1999.
Antipsychotic polypharmacy and early death.
British Journal of Psychiatry,
Vol. 174,
Issue. 4,
p.
368.
Brambilla, Paolo
Monzani, Emiliano
Alessandri, Mariella
Frova, Maria
Barbui, Corrado
and
Erlicher, Arcadio
1999.
Psychotropic drug use in an Italian psychiatric hospital: a two-year follow-up study.
Epidemiology and Psychiatric Sciences,
Vol. 8,
Issue. 4,
p.
262.
Lindström, Eva
and
Bingefors, Kerstin
2000.
Patient Compliance with Drug Therapy in Schizophrenia.
PharmacoEconomics,
Vol. 18,
Issue. 2,
p.
105.
Sajatovic, Martha
Madhusoodanan, Subramoniam
and
Buckley, Peter
2000.
Schizophrenia in the Elderly.
CNS Drugs,
Vol. 13,
Issue. 2,
p.
103.
Dernovsek, Mojca Z
Bah, Bojana
Pintaric, Leonarda
and
Tavcar, Rok
2000.
The knowledge of inpatients with schizophrenia on their medication at hospital discharge.
Pharmacoepidemiology and Drug Safety,
Vol. 9,
Issue. 4,
p.
327.
Buckley, Nicholas A.
and
Sanders, Prashanthan
2000.
Cardiovascular Adverse Effects of Antipsychotic Drugs.
Drug Safety,
Vol. 23,
Issue. 3,
p.
215.
Bouchard, Roch Hugo
Demers, Marie-France
Simoneau, Isabelle
Alméras, Natalie
Villeneuve, Julie
Mottard, Jean-Pierre
Cadrin, Camille
Lemieux, Isabelle
and
Després, Jean-Pierre
2001.
Atypical Antipsychotics and Cardiovascular Risk in Schizophrenic Patients.
Journal of Clinical Psychopharmacology,
Vol. 21,
Issue. 1,
p.
110.
Ames, David
Camm, John
Cook, Peter
Falkai, Peter
Gury, Charles
Hurley, Rod
Johnson, Gordon
Piepho, Robert
and
Vieweg, Victor
2002.
Minimizing the Risks Associated with Significant QTc Prolongation in People with Schizophrenia: A Consensus Statement by The Cardiac Safety in Schizophrenia Group.
Australasian Psychiatry,
Vol. 10,
Issue. 2,
p.
115.
Haddad, Peter M.
and
Anderson, Ian M.
2002.
Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death.
Drugs,
Vol. 62,
Issue. 11,
p.
1649.
Taylor, David
2002.
Antipsychotic prescribing – time to review practice.
Psychiatric Bulletin,
Vol. 26,
Issue. 11,
p.
401.
Ryan, Martina C.M.
and
Thakore, Jogin H.
2002.
Physical consequences of schizophrenia and its treatment.
Life Sciences,
Vol. 71,
Issue. 3,
p.
239.
2002.
Polypharmacy in Psychiatry.
p.
1.
Montout, Christine
Casadebaig, Francoise
Lagnaoui, Rajaa
Verdoux, Helene
Philippe, Alain
Begaud, Bernard
and
Moore, Nicholas
2002.
Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.
Schizophrenia Research,
Vol. 57,
Issue. 2-3,
p.
147.
Oepen, Godehard
2002.
Polypharmacy in Psychiatry.
p.
101.
Freudenreich, O.
and
Goff, D. C.
2002.
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.
Acta Psychiatrica Scandinavica,
Vol. 106,
Issue. 5,
p.
323.
Lawrence, David M.
D'Arcy, Cashel
Holman, J.
Jablensky, Assen V.
and
Hobbs, Michael S. T.
2003.
Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980–1998.
British Journal of Psychiatry,
Vol. 182,
Issue. 1,
p.
31.
Karow, Anne
and
Lambert, Martin
2003.
Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon.
Current Opinion in Psychiatry,
Vol. 16,
Issue. 6,
p.
713.
Jablensky, A.
2003.
Schizophrenia.
p.
203.
Morgan, Maria G
Scully, Paul J
Youssef, Hanafy A
Kinsella, Anthony
Owens, John M
and
Waddington, John L
2003.
Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland.
Psychiatry Research,
Vol. 117,
Issue. 2,
p.
127.
Green, Alan I
Canuso, Carla M
Brenner, Mark J
and
Wojcik, Joanne D
2003.
Detection and management of comorbidity in patients with schizophrenia.
Psychiatric Clinics of North America,
Vol. 26,
Issue. 1,
p.
115.
eLetters
No eLetters have been published for this article.